Scientists from Waters and Pfizer collaborated to take on the challenge of engineering a novel reversed-phase LC column for high-throughput separations with enhanced resolution, selectivity, and recovery of target mAbs and ADCs.
We listened and learned how scientists separate mAbs and ADCs; then we designed a novel column for LC-MS bioseparations A critical step toward the prolific and successful use of monoclonal antibodies (mAb) as biotherapeutics occurred… Read more >
A new approach to stationary phase chemistry for reversed-phase LC analysis of proteins, including monoclonal antibodies and antibody drug conjugates, delivers higher fidelity data especially for MS-based peak identification.
Ken Fountain, Director of Biopharmaceutical Business Development at Waters, recently returned from an insightful trip to Asia where he visited Waters customers in South Korea and attended the China Biopharma Executive Summit in Shanghai, in… Read more >
Bioanalysis of Antibody Drug Conjugates in the Spotlight Few, if any, of the joggers along Boston’s Charles River could have realized the anticipation contained within the Hyatt Cambridge on a recent September Sunday morning. In… Read more >
Increasing Size, Complexity and Potency: The Bioanalytical Challenge of the Next Decade, was the theme for the 3-day APA India held in Mumbai, India from February 23-25, 2015. Close to 300 attendees gathered to discuss… Read more >
One of the opportunities for personalized medicine is that by targeting a disease, can you eliminate the side effects of the cure? Antibody drug conjugates (ADCs) are one next-generation therapeutic approach that may have an… Read more >